Bilirubin Nanomedicine Rescues Intestinal Barrier Destruction and Restores Mucosal Immunity in Colitis

Cited 14 time in webofscience Cited 0 time in scopus
  • Hit : 96
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorRahman, Afia Tasnimko
dc.contributor.authorShin, Jongohko
dc.contributor.authorWhang, Chang-Heeko
dc.contributor.authorJung, Wonsikko
dc.contributor.authorYoo, Dohyunko
dc.contributor.authorSeo, Changjinko
dc.contributor.authorCho, Byung-Kwanko
dc.contributor.authorJon, Sangyongko
dc.date.accessioned2023-07-04T01:01:03Z-
dc.date.available2023-07-04T01:01:03Z-
dc.date.created2023-07-03-
dc.date.created2023-07-03-
dc.date.issued2023-05-
dc.identifier.citationACS NANO, v.17, no.11, pp.10996 - 11013-
dc.identifier.issn1936-0851-
dc.identifier.urihttp://hdl.handle.net/10203/310225-
dc.description.abstractInflammatory bowel disease (IBD) manifests as intestinalbarrierdestruction, mucosal immunity dysregulation, and disrupted gut microbiomehomeostasis. Conventional anti-inflammatory medications for IBD therapypartially alleviate symptoms but are unable to restore normal barrierand immune function. Here, we report a nanomedicine comprising bilirubin(BR)-attached low-molecular-weight, water-soluble chitosan nanoparticles(LMWC-BRNPs), that promotes restoration of the intestinal barrier,mucosal immunity, and the gut microbiome, thereby exerting robusttherapeutic efficacy. In a mouse model of dextran sulfate sodium salt(DSS)-induced colitis, orally administered LMWC-BRNPs were retainedin the GI tract much longer than other nonmucoadhesive BRNPs owingto the mucoadhesiveness of LMWC via electrostatic interaction. Treatmentwith LMWC-BRNPs led to considerable recovery of the damaged intestinalbarrier compared with the current IBD medication, 5-aminosalicylicacid (5-ASA). Orally administered LMWC-BRNPs were taken up by pro-inflammatorymacrophages and inhibited their activity. They also concurrently increasedthe population of regulatory T cells, thereby leading to the recoveryof dysregulated mucosal immunity. An analysis of the gut microbiomerevealed that LMWC-BRNPs treatment significantly attenuated the increase Turicibacter, an inflammation-related microorganism, resultingin protection of gut microbiome homeostasis. Taken together, our findingsindicate that LMWC-BRNPs restored normal functions of the intestineand have high potential for use as a nanomedicine for IBD therapy.-
dc.languageEnglish-
dc.publisherAMER CHEMICAL SOC-
dc.titleBilirubin Nanomedicine Rescues Intestinal Barrier Destruction and Restores Mucosal Immunity in Colitis-
dc.typeArticle-
dc.identifier.wosid001006767700001-
dc.identifier.scopusid2-s2.0-85162225416-
dc.type.rimsART-
dc.citation.volume17-
dc.citation.issue11-
dc.citation.beginningpage10996-
dc.citation.endingpage11013-
dc.citation.publicationnameACS NANO-
dc.identifier.doi10.1021/acsnano.3c03252-
dc.contributor.localauthorCho, Byung-Kwan-
dc.contributor.localauthorJon, Sangyong-
dc.description.isOpenAccessN-
dc.type.journalArticleArticle-
dc.subject.keywordAuthorBilirubin-
dc.subject.keywordAuthorBilirubin nanoparticles-
dc.subject.keywordAuthorLow-molecular-weightchitosan-
dc.subject.keywordAuthorInflammatory bowel disease-
dc.subject.keywordAuthorOral delivery-
dc.subject.keywordPlusINFLAMMATORY-BOWEL-DISEASE-
dc.subject.keywordPlusDSS-INDUCED COLITIS-
dc.subject.keywordPlusCONJUGATED CHITOSAN-
dc.subject.keywordPlusULCERATIVE-COLITIS-
dc.subject.keywordPlusORAL DELIVERY-
dc.subject.keywordPlusNANOPARTICLES-
dc.subject.keywordPlusMICROBIOTA-
dc.subject.keywordPlusMICE-
dc.subject.keywordPlusPLATFORM-
dc.subject.keywordPlusMODELS-
Appears in Collection
BS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 14 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0